Pyrophosphate as a biomarker for artery hardening in type 2 diabetes
Part of Hormones & metabolism clinical trials.
This study looks at a substance in the blood called pyrophosphate that may help doctors detect a type of artery hardening (mediacalcinosis) in people with type 2 diabetes. It tests whether this substance can be a useful early warning sign.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man between 40 and 70 years old.
- You have type 2 diabetes that has lasted at least 6 months.
- You take a medication called an SGLT2 inhibitor (like canagliflozin, dapagliflozin, or empagliflozin).
- You do not have advanced kidney disease (stage 3 or worse).
- You live in the Alpes-Maritimes or Var area of France.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at fat stored around the heart in people with type 2 diabetes, using samples already collected from a larger study. Researchers want to understand how this fat relates to diabetes, but it does not test any new drug or treatment.
This study looks at differences in body fat to understand why some people develop type 2 diabetes. You may be asked for blood tests and health information to see if your diabetes risk and body fat patterns are linked.
This early study looks at how “autophagy” (your body’s cell recycling process) relates to small blood-vessel problems in people with type 2 diabetes. It may help researchers understand mechanisms and possible future treatments, mainly for people who meet specific health and medication criteria.
This study looks at how platelets (the cells that help your blood clot) change in people with type 2 diabetes. It may help doctors understand diabetes better and find new ways to manage it.
This study looks at how the liver uses energy (mitochondria) in people with type 2 diabetes and fatty liver disease. By understanding this, researchers may find better ways to treat liver problems.
This study measures immune cells from your blood to find markers (biomarkers) that may explain or predict diabetic cardiomyopathy, a type of heart condition linked to diabetes. You may benefit mainly by being closely monitored and contributing to research that could improve future diagnosis or risk tracking.
Hear when a new Type 2 diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.